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Lysosomal damageClaudins are tight junctional proteins and comprise a family of over 20 members. Abnormal expression of
claudins is reported to be involved in tumor progression. Claudin-2 is highly expressed in lung adenocarcinoma
tissues and increases cell proliferation, whereas it is not expressed in normal tissues. Claudin-2-targeting
molecules such as peptides and small molecules may be novel anti-cancer drugs. The short peptide with the
sequence DFYSP, which mimics the second extracellular loop of claudin-2, decreased claudin-2 content in the
cytoplasmic fraction of A549 cells. In contrast, it did not affect the content in the nuclear fraction. The decrease
in claudin-2 content was inhibited by chloroquine (CQ), a lysosomal inhibitor, but not byMG-132, a proteasome
inhibitor. In the presence of DFYSP peptide and CQ, claudin-2was co-localizedwith LAMP-1, a lysosomalmarker.
The DFYSP peptide-induced decrease in claudin-2 content was inhibited by monodancylcadaverine (MDC), an
inhibitor of clathrin-dependent endocytosis. DFYSP peptide increased lysosome content and cathepsin B release,
and induced cellular injury, which were inhibited by MDC. Cellular injury induced by DFYSP peptide was
inhibited by necrostatin-1, an inhibitor of necrotic cell death, but not by Z-VAD-FMK, an inhibitor of apoptotic
cell death. Our data indicate that DFYSP peptide increases the accumulation of the peptide and claudin-2 into
the lysosome, resulting in lysosomal damage. Claudin-2 may be a new target for lung cancer therapy.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
At the apical pole of the intercellular junction of the lateral mem-
brane, epithelial cells form the tight junctions (TJs), which compose a
large complex of proteins including transmembrane and scaffolding
proteins [1]. The TJs separate the apical and basolateral epithelial com-
partments to produce their polarization and create a primary barrier
to prevent and control the diffusion of solutes across the epithelial
sheet. Claudins are the most important structural and functional com-
ponents of tight junctional integral membrane protein. They comprise
a family of over 20 members and bear a common structure of fourmidino-2-phenylindole; ECL,
onodancylcadaverine; NSCLC,
dT-mediated dUTP-biotin nick
nyl)-2-(4-nitrophenyl)-2H-5-
eu-Leucinal; VAD-FMK, Z-Val-
ochemistry, Department of
sity, 1-25-4 Daigaku-nishi, Gifutransmembrane domains with a short cytoplasmic N-terminus, two
extracellular loops (ECLs) and a C-terminal cytoplasmic domain [2,3].
Different combinations of claudins can confer different properties to ep-
ithelial cells in terms of physiological and pathophysiological functions
[4].
The expression levels of claudins are altered in tumors isolated from
gastrointestinal tract, colon, breast, ovary, pancreas, liver, and prostate
tissues, and affect the development of cancer cells [5]. We recently re-
ported that human lung adenocarcinoma tissue and cells highly express
claudin-2, which is absent in normal lung tissue [6]. Cell proliferation
and invasion are suppressed by claudin-2 knock down. Similarly,
claudin-2 promotes proliferation in colon cancer cells [7] and breast
cancer livermetastasis in vivo [8], and invasion in colon, lung, and stom-
ach cells [9].
Claudins interact by side-to-side binding in one membrane and by
head-to-head binding between adjacent cells. The homomeric and
heteromeric complexes of claudins in epithelial cells determine the
characteristics of the TJs. Normal lung epithelia express claudin-1,−3,
−4,−5,−7, and−18, whereas the expression levels of these claudins
are low or absent in human lung adenocarcinoma A549 cells [10–12].
Claudin-2 may mainly form a homomeric complex in A549 cells,
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Fig. 1. Decrease in claudin-2 content of cytoplasmic fraction by DFYSP peptide. (A and B) A549 cells were treated with DFYSP or random peptide at indicated concentration for 24 h.
Cytoplasmic extracts including membrane and cytoplasmic proteins were immunoblotted with anti-claudin-1, claudin-2, or β-actin antibody. The contents of claudin-1 and claudin-2
are represented relative to the values in 0 μM. (C) Nuclear extracts were immunoblotted with anti-claudin-2 or nucleoporin p62 antibody. The content of claudin-2 in the cells treated
with DFYSP (open columns) or random peptide (hatched columns) is represented relative to the values in 0 μM. (D) Cells were treated with 500 μM DFYSP peptide in the presence
and absence of 10 μMMG-132 or 100 μM CQ for 24 h. Cytoplasmic extracts were immunoblotted with anti-claudin-1, claudin-2, or β-actin antibody. The contents of claudin-1 and
claudin-2 are represented relative to the values in control. n = 3–4. Statistical comparison was made by Dunnett's (A–C) or Tukey's (D) test. **P b 0.01 signiﬁcantly different from
0 μM or control. ##P b 0.01 signiﬁcantly different from DFYSP. NS, not signiﬁcantly different.
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2328 A. Ikari et al. / Biochimica et Biophysica Acta 1848 (2015) 2326–2336because the content of claudin-2 is high. The barrier function of the TJs
is prevented by peptides derived from occludin [13], another TJ-
associated protein, and speciﬁc claudin ligands [14,15]. Dabrowski
et al. [16] recently reported that the ﬁrst ECL of claudin-1 constitutes a
functional β-sheet binding surface and a shielded redox-sensitive di-
sulﬁde bridge. A peptide and a recombinant protein of the ECL of
claudin-1 are selectively associated with claudin-1, decrease claudin-1
level, and increase the paracellular permeability. On the other hand,
DFYNP, a small peptide that mimics the second ECL of claudin-3 and
-4, increases internalization of these claudins in mammary epithelial
cells [17]. The inhibition of claudin–claudin interaction by the peptide
may cause internalization of claudins. Claudin-2 may be a target for
lung adenocarcinoma therapy because the knock down of claudin-2 de-
creases proliferation andmigration in A549 cells [6,12]. However, it has
not been clariﬁedwhat peptide can interactwith claudin-2 andwhether
the peptide affects cell survival.
In the present study, we found that DFYSP peptide, which mimics
the second ECL of claudin-2, decreases claudin-2 content of the cyto-
plasmic fraction in A549 cells. The DFYSP peptide-induced decrease in
claudin-2 was inhibited by monodancylcadaverine (MDC), an inhibitor
of clathrin-dependent endocytosis, and chloroquine (CQ), a lysosomal
inhibitor. DFYSP peptide increased lysosome content and cathepsin B
release, and induced cellular injury. Our data indicate that DFYSP pep-
tide causes cell death in the claudin-2-expressing adenocarcinoma
cells mediated by lysosomal damage.
2. Materials and methods
2.1. Materials
Anti-claudin-1, claudin-2, claudin-3, claudin-4, and zonula occludens-
1 (ZO-1) antibodieswere obtained fromZymed Laboratories (South San
Francisco, CA, USA). Anti-LAMP-1 and nucleoporin p62 antibodies were
from Becton Dickinson Biosciences (San Jose, CA, USA). 4′,6-diamidino-
2-phenylindole (DAPI) was from Dojindo Laboratories (Kumamoto,
Japan). MDC was from Sigma-Aldrich (Saint Louis, MO, USA). CQ,Claudin-3
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Fig. 2.Effect of DFYSPpeptide on claudin-3 and -4 contents. A549 cellswere transfectedwith cla
presence and absence of 500 μM DFYSP peptide for 24 h. Cytoplasmic extracts including mem
antibody. The contents of claudin-3 and -4 are represented relative to the values in the absencecytochalasin B (CytB), and methyl-β-cyclodextrin (MβCD) were from
Wako Pure Chemical Industries (Osaka, Japan). LysoTracker Red DND-
99 was from Life Technologies (Gaithersburg, MD, USA). Z-Leu-Leu-
Leucinal (MG-132), etoposide, and Z-Val-Ala-Asp-ﬂuoromethylketone
(Z-VAD-FMK) were from Enzo Life Sciences (Farmingdale, NY, USA).
DFYSP and random (SFPDY) peptides were synthesized in Medical &
Biotechnological Laboratories (Nagoya, Japan). Fluorescein isothiocya-
nate (FITC)-labeled DFYSP and random peptides were synthesized in
GenScript (Piscataway, NJ, USA). All other reagents were of the highest
grade of purity available.
2.2. Plasmid cDNA constructs
Human claudin-3 and−4were ampliﬁed by polymerase chain reac-
tion using the set of primers, 5′-CATGTCCATGGGCCTGGAG-3′ (claudin-
3: sense), 5′-TTAGACGTAGTCCTTGCGG-3′ (claudin-3: antisense), 5′-
CATGGCCTCCATGGGGCTAC-3′ (claudin-4: sense), and 5′-CTACACGT
AGTTGCTGGC-3′ (claudin-4: antisense). The cDNAs were subcloned
into pCMV-Tag2 vector (Stratagene, La Jolla, CA, USA).
2.3. Cell culture and transfection
A549 cell line was obtained from the RIKEN BRC through the Na-
tional Bio-Resource Project of the MEXT, Japan. Cells were grown in
Dulbecco's modiﬁed Eagle's medium (Sigma-Aldrich) supplemented
with 5% fetal calf serum (HyClone, Logan, UT), 0.07 mg/ml penicillin-G
potassium, and 0.14 mg/ml streptomycin sulfate in a 5% CO2 atmo-
sphere at 37 °C. Claudin-2 knock down (KD)/A549 cells were estab-
lished previously [12]. The expression of claudin-2 was suppressed by
the addition of 1 μg/ml doxycycline in the media.
2.4. SDS-polyacrylamide gel electrophoresis
(SDS-PAGE) and immunoblotting
Nuclear and cytoplasmic extracts were prepared using NE-PER
nuclear and cytoplasmic extraction reagents (Thermo Fisher Scientiﬁc,Claudin-4
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of peptide. n= 4. Statistical comparisonwasmade by t test. NS, not signiﬁcantly different.
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Fig. 3. Cellular localization of junctional proteins. (A and B) A549 cells were treatedwith 500 μMDFYSP or random peptide for 24 h and stainedwith claudin-1 (red), claudin-2 (red), ZO-1
(green), andDAPI (blue). (C andD)Cellswere treatedwithDFYSPor randompeptide in thepresenceof 100 μMCQfor 2 h and stainedwith claudin-1, claudin-2, LAMP-1 (green), andDAPI.
The scale bar represents 10 μm. (E) The co-localization region between the claudins and LAMP-1wasmanuallymarked using ImageJ. The intensity of the co-localization region is shown as
a percentage of the total intensity of claudin-1 or claudin-2 in the cytoplasmic and junctional regions. The scale bar represents 10 μm. n=6–8. Statistical comparisonwasmade by Tukey's
test. **P b 0.01 signiﬁcantly different from control. NS, not signiﬁcantly different.
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cytoplasmic extracts includemembrane and cytosolic proteins. Samples
were applied to SDS-PAGE and blotted onto a PVDF membrane. The
membrane was then incubatedwith each primary antibody (1:1000 di-
lution) at 4 °C for 16 h, followed by a peroxidase-conjugated secondary
antibody (1:5000 dilution) at room temperature for 1 h. Finally, the
blots were incubated in Pierce Western Blotting Substrate (Thermo
Fisher Scientiﬁc, Waltham, MA) and exposed to ﬁlm, or incubated in
ECL Prime Western Blotting Detection System (GE Healthcare UK Ltd.)
and scanned with a C-DiGit Blot Scanner (LI-COR Biotechnology,
Lincoln, NE). Band density was quantiﬁed with ImageJ software0 30A
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Fig. 4. Time-dependent internalization of FITC-labeled DFYSP peptide. (A) Claudin-2 KD/A549 c
were treated with 500 μM FITC-labeled DFYSP peptide from 0 to 120 min in the presence of D
(B) A549 cells were incubated with FITC-labeled DFYSP or random peptide in the presence of(National Institute of Health software). β-Actin or nucleoporin p62
was used for normalization.
2.5. Immunocytochemistry
Cells were cultured on cover glasses and treated with peptides and
CQ. The cells were ﬁxed with methanol for 10 min at −20 °C, then
permeabilized with 0.2% Triton X-100 for 15 min. After blocking with
2% Block Ace (Dainippon Sumitomo Pharma, Osaka, Japan) for 30 min,
the cells were incubated with anti-claudin-1, claudin-2, ZO-1, or
LAMP-1 antibody for 16 h at 4 °C. They were then incubated with60 120 min
LysoTracker Merge
ells were incubated in the presence (+Dox) and absence (−Dox) of doxycycline. The cells
API (blue). Middle panels show enlarged view of the enclosed area in the upper panels.
LysoTracker (red), 100 μM CQ, and DAPI for 1 h. The scale bar represents 10 μm.
2331A. Ikari et al. / Biochimica et Biophysica Acta 1848 (2015) 2326–2336Alexa Fluor 488 and 543-conjugated antibodies includingDAPI for 1 h at
room temperature. Immunolabeled cells were visualized on LSM 510 or
LSM 700 confocal microscope (Carl Zeiss, Germany) set with a ﬁlter
appropriate for DAPI, Alexa Fluor 488, and Alexa Fluor 543. The co-
localization region between claudins and LAMP-1 was manually
marked using ImageJ. The intensity of the co-localization region was
shown as a percentage of total intensity of claudin-2 in the cytoplasmic
and junctional regions.
2.6. Live cell imaging
Cells were cultured on glass-bottom 35-mm tissue culture dishes
(Matsunami Glass, Osaka) and incubated with FITC-labeled peptides
and LysoTracker Red DND-99 for the periods indicated. After washing
with phosphate buffered saline, the cells were visualized on LSM 510
or LSM 700 confocal microscope set with a ﬁlter appropriate for DAPI,
FITC, and LysoTracker Red.
2.7. Cellular injury assay
Cells were seeded at 8 × 103 cells/well in a 96-well plate in 100 μl
medium. After 24-h culture, the cells were incubated with peptides for
24 h and then cellular injury was assessed using the tetrazolium salt
4-[3-(4-lodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene
disulfonate (WST-1). Cells were incubated with WST-1 for 1 h at 37 °C.
The absorbance of WST-1 was measured at 450 nm, with background
subtraction at 655 nm, using a Model 680 Microplate Reader (Bio-RadClaudin-2
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Fig. 5. Inhibition of DFYSP-peptide-induceddecrease in claudin-2 byMDC. A549 cellswere treat
10 μM CytB for 24 h. (A) Cytoplasmic extracts including membrane and cytoplasmic proteins
claudin-1 and claudin-2 were represented relative to the values in control. (B) The cells wer
10 μm. n = 3–4. Statistical comparison was made by Tukey's test. **P b 0.01 signiﬁcantly differLaboratories, Hercules, CA, USA). The decrease in the absorbance value
is considered a cellular injury.
2.8. Lysosome assay
Cells were plated on cover glasses and treatedwith peptides and CQ.
Then the cells were labeled using reagent of a Lyso-ID Red Lysosomal
Detection Kit (Enzo Life Sciences, PlymouthMeeting, PA, USA). A nuclear
counter stainwas performedwithDAPI. Immunolabeled cellswere visu-
alized on an LSM 510 confocal microscope. Using ImageJ software, the
Lyso-ID red-staining areawas traced and analyzed in 6–8 representative
ﬁelds of 4 different samples. The ﬂuorescence intensity of the Lyso-ID
red was determined by measuring the mean pixel density of staining
area in each cell. After subtraction of background, the intensity values
were shown as arbitrary units relative to control.
2.9. Cathepsin B activity assay
Cells were seeded at 5 × 104 cells/well in a 24-well plate and, 24 h
later, were treated with peptides and CQ. After removal of the media,
cytoplasmic and total cathepsins were extracted as described else-
where [18]. The activity of cathepsin B was measured by Cathepsin
B Activity Fluorometric Assay Kit (BioVision, Milpitas, CA, USA)
according to the manufacturer's instructions. The ﬂuorescence of
amino-4-triﬂuoromethyl coumarin was quantiﬁed by GloMax-Multi+
MicroplateMultimode Reader (Promega,Madison,WI, USA) (excitationZO-1 Claudin-2 Merge (+DAPI)
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Fig. 6. Induction of cellular injury by DFYSP peptide. (A) Claudin-2 KD/A549 cells were
treated with DFYSP or random peptide in the absence of doxycycline for 24 h. Cellular
injury was assessed using WST-1. (B) Claudin-2 KD/A549 cells were treated with DFYSP
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Statistical comparison was made by Tukey's test. ** and ##P b 0.01, signiﬁcantly different
from control and DFYSP, respectively. NS, not signiﬁcantly different from DFYSP.
2332 A. Ikari et al. / Biochimica et Biophysica Acta 1848 (2015) 2326–2336at 405 nm, emission at 505 nm). The cytoplasmic cathepsin B was
expressed as the percentage of total cathepsin B.
2.10. Apoptosis assay
Cells were treated with peptides or etoposide for 24 h. Apoptotic
cells were determined using Annexin V-FITC Apoptosis Kit (BioVision)
andDeadEnd Fluorometric TdT-mediated dUTP-biotin nick end labeling
(TUNEL) System (Promega). Annexin V and TUNEL stainings were per-
formed according to the manufacturer's instructions. The cells were
visualized on a ﬂuorescence microscope (BZ-9000, Keyence, Osaka,
Japan). 4–6 representative ﬁelds were scored. The numbers of cells
stained by only Annexin V-FITC (annexin V staining) or ﬂuorescein-
12-dUTP (TUNEL staining) were counted and expressed as a percentage
of the total cell number.
2.11. Statistics
Results are presented asmeans±S.E.M. Differences between groups
were analyzed with a one-way analysis of variance, and corrections for
multiple comparison were made using Tukey's and Dunnett's multiple
comparison tests. Comparisons between two groups were made using
Student's t test. Signiﬁcant differences were assumed at p b 0.05.
3. Results
3.1. Decrease in claudin-2 content by DFYSP peptide
Claudin-2 is highly expressed in A549 cells and human lung adeno-
carcinoma tissue compared with that in normal lung tissue [12]. DFYSP
peptide decreased claudin-2 content in the cytoplasmic fraction in a
dose-dependent manner, whereas random peptide did not (Fig. 1A
and B). Claudin-1 content was unchanged by the treatments with
these peptides. Neither DFYSP nor random peptide decreased claudin-
2 content in the nuclear fraction (Fig. 1C). Claudin-1 was not detected
in the nuclear fraction (data not shown). To investigate the selectivity
of DFYSP peptide, we examined the effect of DFYSP peptide on the con-
tents of claudin-3 and -4. We ectopically expressed claudin-3 or -4 in
A549 cells, because the cells have little expression of these claudins.
DFYSP peptide decreased neither claudin-3 nor claudin-4 contents
(Fig. 2). These results indicate that DFYSP peptide selectively decreases
claudin-2 content. The DFYSP peptide-induced decrease in claudin-2
content was blocked by CQ, a lysosomal inhibitor, but not by MG-132,
a proteasome inhibitor (Fig. 1D). In contrast, these inhibitors did not
change claudin-1 content. These results indicate that DFYSP peptide in-
creases the degradation of claudin-2 by lysosomal enzymes.
3.2. Effects of peptides on the cellular localization of claudin-2
Immunoﬂuorescencemeasurements showed that claudin-2 is local-
ized in the nuclear, cytoplasmic, and cell–cell border area (Fig. 3A). In
contrast, claudin-1 was mainly localized in the cell–cell border area
(Fig. 3B). ZO-1, a tight junctional scaffolding protein, was localized in
the nuclear and cell–cell border area. DFYSP peptide decreased the ﬂuo-
rescence intensity of claudin-2 in the cell–cell border area, but did not
affect that in the nuclei. The cellular localization of claudin-1 and ZO-1
was unchanged by DFYSP and random peptides. These results indicate
that DFYSP peptide selectively decreased claudin-2 content in the plas-
mamembrane. As shown in Fig. 1D, CQ blocked the DFYSP-induced de-
crease in claudin-2 content. Therefore, we examined the effect of DFYSP
peptide on the cellular localization of claudins in the presence of CQ.
DFYSP peptide increased the ﬂuorescence intensity of claudin-2 in the
cytoplasmic compartment, whereas it decreased that in the cell–cell
border area (Fig. 3C). In contrast, the localization of claudin-1 was
unchanged by the treatments with CQ and DFYSP peptide (Fig. 3D).
DFYSP peptide time-dependently increased the co-localization ofclaudin-2 with LAMP-1, a lysosomal marker, without affecting that of
claudin-1 with LAMP-1 (Fig. 3E and Supplementary Fig. 1A). These re-
sults indicate that DFYSP peptide increased the accumulation of
claudin-2 in the lysosome. The treatment of the cells with CQ alone for
8 h increased the co-localization of claudin-2 and LAMP-1 (Supplemen-
tary Fig. 1B), indicating that claudin-2 was also transported into the
lysosome under physiological conditions.
2333A. Ikari et al. / Biochimica et Biophysica Acta 1848 (2015) 2326–23363.3. Internalization of FITC-labeled DFYSP peptide
Claudin-2 expression is suppressed by the addition of doxycycline in
claudin-2 KD/A549 cells [12]. Doxycycline decreased claudin-2 expres-
sion without affecting the cellular localization of claudin-1 and ZO-1
(Supplementary Fig. 2). FITC-labeled DFYSP peptide was time-
dependently internalized in claudin-2 KD/A549 cells untreated with
doxycycline (Fig. 4A). In contrast, the binding and internalization of
FITC-labeled DFYSP were not detected in the cells treated with doxycy-
cline. These results indicate that the internalization of DFYSP peptide is
related to claudin-2 expression. The ﬂuorescence intensity of FITC-
labeled DFYSP peptide in the nuclei was not increased by the incubation
of the peptide in the presence and absence of doxycycline (Supplemen-
tary Fig. 3), indicating that FITC-labeled DFYSP peptidewas internalized
into the cytosol, but not distributed in the nuclei. To investigatewhether
FITC-labeled DFYSP peptidewas co-localizedwith claudin-2 in the cyto-
sol, the cellswere ﬁxedwithmethanol and incubatedwith anti-claudin-
2 antibody. However, we could not detect the ﬂuorescence of FITC-
labeled DFYSP peptide (Supplementary Fig. 4). Therefore, we examined
the cellular localization of FITC-labeled DFYSP peptide in the living cells
using LysoTracker, a lysosomal marker. FITC-labeled DFYSP peptide was
co-localized with LysoTracker (Fig. 4B). In contrast, there is little co-
localization of FITC-labeled random peptide with LysoTracker. These
results indicate that FITC-labeled DFYSP peptide was internalized into
the lysosome similarly to claudin-2.Lyso-ID Lyso-ID+DAPI
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endocytosis inhibitor
Weexamined the effects of pharmacological inhibitors on the DFYSP
peptide-induced decrease in claudin-2 content. MDC, an inhibitor of
clathrin-dependent endocytosis, blocked the DFYSP peptide-induced
decrease in claudin-2 content (Fig. 5A). In contrast, MβCD, an inhibitor
of caveola-dependent endocytosis, and CytB, an inhibitor of actin-
dependent endocytosis had no effects. Immunoﬂuorescence measure-
ments showed that claudin-2 is co-localizedwith ZO-1 in the TJs of con-
trol cells and the cells treated with DFYSP peptide plus MDC (Fig. 5B).
Tight junctional claudin-2 disappeared by the treatment with DFYSP
peptide, whichwas not inhibited byMβCD and CytB. These results indi-
cate that DFYSP peptide increases the internalization of claudin-2medi-
ated via a clathrin-dependent pathway.
3.5. Induction of cellular injury by DFYSP peptide
We examined whether DFYSP peptide causes cellular injury
using claudin-2-KD/A549 cells. DFYSP and random peptides dose-
dependently induced cellular injury in the claudin-2-expressing A549
cells (Fig. 6A). The amount of cellular injury induced by DFYSP peptide
was signiﬁcantly higher than that by random peptide at 50, 100, and
500 μM. Both DFYSP and random peptides slightly induced cellular
injury in the claudin-2-KD/A549 cells treated with doxycycline, butCo
nt
ro
l
Lyso-ID Lyso-ID+DAPI
CQ
0
3.0
R
FI
of
Ly
so
-
ID
C o
n
tro
l
2.0
1.0
R
a
n
do
m
D
FY
SP CQ
**
**
NS
for 24 h. Cellular injurywas assessed usingWST-1. (B and C) Cellswere treatedwith 70 μM
s were collected after staining with Lyso-ID red and DAPI. The scale bar represents 10 μm.
ive to control (RFI). n = 4–6. Statistical comparison was made by Tukey's test. **P b 0.01,
2334 A. Ikari et al. / Biochimica et Biophysica Acta 1848 (2015) 2326–2336the amount is not signiﬁcantly different (Fig. 6B). Cellular injury in-
duced by DFYSP peptide was signiﬁcantly inhibited by MDC, but not
by MβCD and CytB (Fig. 6C). These results are consistent with those in
Western blotting and immunocytochemistry, indicating that the
clathrin-dependent endocytic pathway is involved in the cellular injury
induced by DFYSP peptide.
3.6. Induction of necrosis by DFYSP peptide
As shown in Fig. 3, DFYSP peptide increased the localization of
claudin-2 in the lysosome. Therefore, we examined the involvement
of lysosome on the DFYSP-peptide induced cellular injury. CQ induced
cellular injury in a dose-dependent manner (Fig. 7A). The ﬂuorescence
intensity of Lyso-ID was increased by CQ (Fig. 7B and D), indicating
that CQ increased lysosome content. Similarly, the ﬂuorescence intensi-
ty of Lyso-ID was increased by DFYSP peptide (Fig. 7C and D). In con-
trast, random peptide had no effect. Uncontrolled release of lysosomal
proteases into the cytosol can exacerbate the ongoing cell death. The re-
lease of cathepsin B, a lysosomal protease, was increased by DFYSP pep-
tide and CQ (Fig. 8A). Cellular injury induced by DFYSP peptide was
signiﬁcantly suppressed by necrostatin-1, a necrosis inhibitor, but not
by Z-VAD-FMK, an apoptosis inhibitor (Fig. 8B). In contrast, neither
necrostatin-1 nor Z-VAD-FMK changed cellular injury in the cells treat-
ed with random peptide. To deny the involvement of apoptosis, we
examined annexin V and TUNEL stainings. Etoposide, an apoptosis in-
ducer, increased Annexin V and TUNEL positive cells (Fig. 8C and D), in-
dicating that the assay performance is reliable. Neither DFYSP nor
random peptides increased the positive cells. These results indicate
that DFYSP peptide causes cell death mediated by the activation of0
60
%
o
fc
a
th
ep
sin
B
re
le
a
se
Co
nt
ro
l
40
20
R
an
do
m
D
FY
SP CQ
A
50
30
10
0
50
Ce
llu
la
ri
n
jur
y
(%
)
Co
nt
ro
l
30
20
D
FY
SP
40
10
B
D E
**
NS
**
**
NS
0
30
%
o
fc
a
th
ep
sin
B
r e
le
as
e
Co
nt
ro
l
20
10
D
FY
SP
N
D
FY
SP
**
0
60
%
of
TU
N
EL
po
si
tv
e
ce
lls
Co
nt
ro
l
40
20
R
a
n
do
m
D
FY
SP
Et
op
os
id
e
50
10
30
**
NS NS
DFYSP
Random
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not signiﬁcantly different from control (A–D) or DFYSP (E and F).necrotic pathway, but not by apoptotic pathway. Next, we examined
the effects of DFYSP peptide and endocytosis inhibitors on the release
of cathepsin B and ﬂuorescence intensity of Lyso-ID. The increases in re-
lease of cathepsin B and ﬂuorescence intensity of Lyso-ID caused by
DFYSP peptide were inhibited by MDC, but not by MβCD and CytB
(Fig. 8E and F). These results are consistent with those in cellular
injury.
4. Discussion
DFYNP peptide, whichmimics the second ECL of claudin-3, -4, -6, -7,
-8, and -9, increases internalization of claudin-3 and -4 inmammary ep-
ithelial cells [17]. Mismatch of a single amino acid of F147, Y148, N149,
and P150 in the peptide loses the activity. These amino acids are crucial
residues to make claudin–claudin interactions in the TJs. In claudin-2,
the amino acid at 149 is Ser, which is different from that in claudin-3,
-4, -6, -7, -8, and -9. We found for the ﬁrst time that a synthetic peptide
DFYSP, amimic of the second ECL of claudin-2, decreases claudin-2 con-
tent in the cytoplasmic fraction of A549 cells (Fig. 1). DFYSP peptide did
not change claudin-1 content, which contains Asp at 149. Furthermore,
the peptide did not change the contents of claudin-3 and -4, which con-
tain Asn at 149. We suggest that DFYSP peptide selectively acts on
claudin-2. The elevation of claudin-2 expression has been reported in
various diseases such as tumors [5], inﬂammatory bowel disease [19],
and necrotizing enterocolitis [20]. Claudin-2 targeting peptides may
be useful for improving the expression of claudin-2.
Many plasmamembrane proteins are internalized from the cell sur-
face by endocytosis and are sorted to their ﬁnal destination by the
endosomal pathway. However, the internalization pathways of tightD
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acetylcholine receptors induces a clathrin-dependent endocytosis of
claudin-4 in rat salivary epithelial SMG-C6 cells [21]. Escherichia coli
toxin cytotoxic necrotizing factor-1, which activates RhoA, induces a ca-
veola-dependent endocytosis of occludin [22]. We found that the inter-
nalization and degradation of claudin-2 by DFYSP peptide are inhibited
byMDC, but not byMβCD and CytB in A549 cells (Fig. 5), indicating that
claudin-2 is internalized via a clathrin-dependent endocytic pathway.
Similarly, epidermal growth factor internalizes claudin-2 mediated via
a clathrin-dependent pathway in Madin–Darby canine kidney type II
cells [23]. Zwanziger et al. [24] reported that the claudin-1 and -5-de-
rived peptides can be internalized by speciﬁc and nonspeciﬁc pathways
including the clathrin-dependent and caveola-dependent pathways,
and macropinocytosis. Each tight junctional protein is internalized by
speciﬁc pathways, but the pathways may be dependent on the types
of junctional proteins, stimuli, and cells.
Little is known about the degradation mechanism of claudins. We
found that CQ inhibits the DFYSP peptide-induced decrease in claudin-
2 content (Fig. 1D) and increases the co-localization of claudin-2 with
LAMP-1 (Fig. 3). We could not detect the co-localization of FITC-labeled
DFYSP peptide with claudin-2 in the lysosome by immunoﬂuorescence
staining, but FITC-labeled DFYSP and claudin-2were co-localizedwith a
lysosomalmarker in the cells treatedwith DFYSP peptide and CQ. These
results indicate that both claudin-2 and DFYSP peptide are transported
into the lysosome and claudin-2 is degraded in the lysosome. The long
term treatment with CQ alone increased the co-localization of claudin-
2 with LAMP-1 in the absence of DFYSP peptide (Supplementary
Fig. 1B). Recently, the knock down of Rab14 has been reported to in-
crease the co-localization of claudin-2 with LAMP-1 [25]. Furthermore,
the knock down of Rab14 decreases claudin-2, which is rescued by the
inhibition of acid proteases. We suggest that claudin-2 is degraded in
the lysosome under physiological conditions. Dephosphorylated
claudin-16 and themutants of claudin-16 associatedwith familial hypo-
magnesemia with hypercalciuria and nephrocalcinosis are localized in
the lysosome [26,27]. Claudin-4 is co-localizedwith LAMP-1 in themul-
tiple PDZ protein 1-silencedmouse innermedullary collecting duct cells
[28]. These reports suggest that lysosomal enzymes are involved in the
degradation of these claudins. On the other hand, claudin-1 and -5 are
ubiquitinated and degraded by proteasomes [29,30]. At present, we do
not knowwhy themechanisms of degradation are different for different
claudins.
Based on morphological criteria, three types of programmed cell
death have been deﬁned: type I apoptotic cell death; type II autophagic
cell death; and type III, which includes necrosis and cytoplasmic cell
death [31]. A peptide containing a four amino acid sequence mimics
the second ECL of occludin, LYHY, causes internalization of occludin
and activation of apoptotic cell death [32]. After treatment with LYHY
peptide for 6 h, occludin and LYHY peptide are co-localized in extra-
junctional patches that contain the death inducing signaling complex,
caspase 3 and 8, the death receptor FAS and the adaptor molecule
FADD. Similarly, DFYNP peptide causes internalization of claudin-3
and -4, and activation of apoptotic cell death in mammary epithelial
cells [17]. However, DFYSP peptide did not induce the activation of ap-
optosis markers in annexin V and TUNEL assays (Fig. 8). Furthermore,
the DFYSP peptide-induced cellular injury was signiﬁcantly inhibited
by necrostatin-1, but not by Z-VAD-FMK. Therefore, apoptotic cell
death may not be involved in the DFYSP-induced cellular injury in
A549 cells. Random peptide did not decrease claudin-2 content, but
slightly induced cellular injury. Furthermore, the random peptide-
induced cellular injury was observed in the claudin-2 knock down
cells. We suggest that the peptides slightly induce cellular injury in a
non-speciﬁc manner. In addition, the inhibitory effect of necrostatin-1
was incomplete. Necrostatin-1 inhibits necrotic cell death that is depen-
dent on receptor-interacting protein 1 (RIP-1) [33]. We suggest that
DFYSP peptide partially induces cellular injury mediated via RIP-1-
independent pathway.Lysosomes contain a variety of proteases, nucleases, glycosidases,
and lipases. Necrotic and apoptotic cell deaths are triggered by a perme-
abilization of lysosomal membrane. Cell death stimuli such as tumor
necrotic factor [34], oxidative stress [35], and growth factor starvation
[36] cause release of cathepsins from the lysosome lumen to the cytosol.
DFYSP peptide increased cathepsin B release, which was inhibited by
MDC (Fig. 8E). The internalization of claudin-2 and DFYSP peptide
may induce expansion of lysosome and lysosomal membrane per-
meabilization (LMP). LMP can be induced by various factors including
reactive oxygen species, lysosomatropic agents, microtubule toxins,
and DNA damage [35]. We need to further study how the internalized
claudin-2 and DFYSP peptide increase LMP and release of cathepsin B
in A549 cells.
In conclusion, we found that DFYSP peptide increases the accumu-
lation of claudin-2 and the peptide into the lysosome, resulting in ly-
sosomal damage. The peptide-induced release of cathepsin B and
cellular injury were inhibited by MDC. Claudin-2 is highly expressed
in human lung adenocarcinoma [6], gastrointestinal carcinoma [37],
and hepatoblastoma [38]. Claudin-2 targeting molecules may be novel
anti-cancer drugs in tumor tissues overexpressing claudin-2.
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